Effects of carvedilol on plasma levels of pro-inflammatory cytokines in patients with ischemic and nonischemic dilated cardiomyopathy

Basit Öğe Kaydı
dc.authorscopusid6601908707
dc.authorscopusid6602577203
dc.authorscopusid57197111786
dc.contributor.authorKurum T.
dc.contributor.authorTatli E.
dc.contributor.authorYuksel M.
dc.date.accessioned2024-06-12T10:28:10Z
dc.date.available2024-06-12T10:28:10Z
dc.date.issued2007
dc.description.abstractWe prospectively investigated the effects of adding carvedilol to the standard treatment of ischemic and nonischemic dilated cardiomyopathy (DCM), by measuring the plasma levels of pro-inflammatory cytokines. Sixty patients with DCM (35 ischemic and 25 nonischemic) were divided into 2 subgroups: patients on standard therapy alone (digoxin, angiotensin-converting enzyme inhibitors, and diuretics) and patients on standard therapy plus carvedilol. Study participants' serum levels of tumor necrosis factor-? (TNF-?), interleukin-2 (IL-2), and interleukin-6 (IL-6) were measured at the beginning and again at the end of the study. Left ventricular ejection fraction and left ventricular diastolic function were evaluated by means of radionuclide ventriculography. In ischemic patients on carvedilol, levels of IL-6 and TNF-? dropped significantly (P=0.028 and P=0.034, respectively). In ischemic patients on standard treatment, plasma IL-2 levels were elevated after treatment (P=0.047). No significant differences occurred in IL-6 levels, while TNF-? levels were elevated (P=0.008). In nonischemic patients on carvedilol, IL-6 and TNF-? levels dropped significantly (P=0.018 and P=0.004, respectively). The left ventricular ejection fraction increased significantly (P=0.006). In nonischemic patients on standard treatment, no significant change occurred in any value. Carvedilol suppressed the plasma levels of TNF-? and IL-6 in both ischemic and nonischemic patients. The carvedilol effect was more pronounced in patients with nonischemic dilated cardiomyopathy than in those with ischemic disease. © 2007 by the Texas Heart® Institute.en_US
dc.identifier.endpage59en_US
dc.identifier.issn0730-2347
dc.identifier.issue1en_US
dc.identifier.pmid17420794en_US
dc.identifier.scopus2-s2.0-34247173884en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage52en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/17112
dc.identifier.volume34en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofTexas Heart Institute Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBiological Markers/Blood; Carbazoles/Therapeutic Use; Cardiomyopathy, Dilated; Carvedilol; Cytokines/Blood; Heart Failure, Congestive; Interleukin-2; Interleukin-6; Tumor Necrosis Factor-Alpha; Ventricular Function, Left/Drug Effectsen_US
dc.subjectCarvedilol; Cytokine; Digoxin; Dipeptidyl Carboxypeptidase Inhibitor; Diuretic Agent; Interleukin 6; Tumor Necrosis Factor Alpha; Article; Blood Level; Congestive Cardiomyopathy; Controlled Study; Drug Effect; Drug Mechanism; Heart Left Ventricle Ejection Fraction; Heart Left Ventricle Enddiastolic Pressure; Human; Major Clinical Study; Protein Blood Level; Radioisotope Ventriculography; Adrenergic Alpha-Antagonists; Adrenergic Beta-Antagonists; Adult; Aged; Blood Pressure; Carbazoles; Cardiomyopathy, Dilated; Cytokines; Female; Heart Rate; Humans; Inflammation Mediators; Interleukin-2; Interleukin-6; Male; Middle Aged; Myocardial Ischemia; Propanolamines; Prospective Studies; Radionuclide Ventriculography; Stroke Volume; Treatment Outcome; Tumor Necrosis Factor-Alpha; Turkey; Vasodilator Agents; Ventricular Function, Leften_US
dc.titleEffects of carvedilol on plasma levels of pro-inflammatory cytokines in patients with ischemic and nonischemic dilated cardiomyopathyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu